619. Invasive Mold Infections (IMIs) in Pediatric Cancer Patients (pts): a Single-Institution, 10 Year Retrospective Study
Session: Abstracts: Mycology
Friday, October 22, 2010
Background: There is scarcity of data regarding opportunistic IMIs in pediatric cancer pts.

Methods: We evaluated all the pediatric pts (<18yo) who developed (probable, proven) IMIs (EORTC/MSG criteria), being diagnosed at our institution over a 10 year period (1998-2008). We retrospectively reviewed the demographic data, risk factors, clinical picture and management of IMI. We assessed crude mortality, complete and partial response at 12 weeks following diagnosis

Results: 48 such pts were identified (30; 63% proven and 18; 37% probable IMI). Out of 35 isolated molds, the most prevalent were Aspergillus spp (14; 40%), Mucorales spp (7; 20%) and Fusarium spp (4; 11%). 44% of the IMI were breakthrough infections. Acute leukemias (39; 81%), active status of malignancy (25; 52%), neutropenia (32; 67%) (<500mm3) and HSCT (20; 42%) were commonly identified. Additionally, high corticosteroid treatment (≥ 600 mg of a prednisone equivalent during the month prior to the diagnosis) (17; 35%), chemotherapeutics (41; 85%) and immunosuppressives (17; 35%) during the previous 2 months further predisposed pediatric pts to IMI. Lungs (77%), skin (29%) and sinonasal (19%) were the most common sites of infection. Therapeutic antifungal regiments combined with growth factors G/GM-CSF (31; 65%) and surgery (18; 38%) resulted in a 33% (16/48) complete and 21% (10/48) partial 12 week response. Crude mortality was 6/48 (12.5%) at 4 weeks and 35% (15/48) at 12 weeks. Female gender (P=0.05) and monocytopenia (P=0.01) were identified by logistic regression as independent risk factors for mortality at 4 weeks.

Conclusion: IMIs in pediatric cancer pts is typically seen in the setting of acute uncontrolled leukemia or HSCT and are associated with significant mortality. Over 60% of the isolated IMIs are due to non-Aspergillus molds. Invasive skin infections are relatively common.

Subject Category: M. Mycology including clinical and basic studies of fungal infections

Georgios Pongas, MD , Infectious Diseases, MD Anderson Cancer Ctr, Houston, TX
Russell Lewis, PharmD , University of Houston College of Pharmacy, Houston, TX
Dimitrios Kontoyiannis, MD, FIDSA , MD Anderson Cancer Ctr, Houston, TX


G. Pongas, None

R. Lewis, Yes
Merck & Co: --, Grant Investigator and Speaker's Bureau, Grant recipient
Astellas: --, Consultant and Grant Investigator, Grant recipient

D. Kontoyiannis, Yes
Enzon: Grant Investigator, Speaker's Bureau and research grants,
Astellas: Grant Investigator, Speaker's Bureau and research grant,
Merck: Consultant, Consultant and Speaker's Bureau,
Pfizer: Speaker's Bureau,
Schering-Plough: Consultant and Consultant,

See more of: Mycology
See more of: Abstracts

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 21 with the exception of research findings presented at IDSA press conferences.


Copyright IDSA 2009 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org